Cite
MLA Citation
Martin Dreyling et al.. “Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.” Lancet, vol. 387, no. 10020, 2016, pp. 770–778. http://access.bl.uk/ark:/81055/vdc_100030783672.0x000023